MAPT and Alzheimer disease: In the setting of well-established biomarkers of AD, the amyloid, tau, neurodegeneration or A/T/N classification staging system has been put forth based on proteinopathy-based imaging, CSF biomarkers, and structural imaging; clinical features are examined for consistency with the biomarkers [34, 35].